Funding Opportunities

T1D Exchange and M2D2 Open the Diabetes Innovation Challenge Request for Applicants
Description: Ambitious initiative aims to excite and incentivize researchers, inventors, entrepreneurs, investors, and the industry to innovate new and inventive approaches to combat diabetes at the inaugural Diabetes Innovation Challenge
Sponsor(s): Massachusetts Medical Device Development Center (M2D2) and T1D Exchange
Application Receipt Dates(s): July 8, 2016
Website: https://t1dexchange.org/pages/t1d-exchange-and-m2d2-open-the-diabetes-innovation-challenge-request-for-applicants/
Human Islet Distribution Coordinating Center (UC4) (RFA-DK-16-023)
Description: This FOA invites applications for continuation of a coordinating center for the Integrated Islet Distribution Program (IIDP). The IIDP facilitates the distribution of human cadaveric islets for biomedical research. The IIDP coordinating center (IIDP-CC) will subcontract with qualified islet isolation facilities to prepare and distribute human islets, and will manage an application process to establish investigator eligibility to receive islets. The IIDP-CC will maintain a roster of researchers approved to receive islets, implement a notification system informing investigators of islet availability, manage a cost recovery system through fees collected from islet recipients, and oversee quality control processes to monitor and improve the quality of islets distributed across the program. Human islets are an essential resource for diabetes research, both to advance our understanding of human islet cell biology and to develop therapies for the treatment of diabetes. The IIDP coordinating center provides critical services to the research community by enhancing access to human islets and by fostering improved standardization and quality of this important research resource.
Sponsor(s): National Institute of Diabetes and Digestive and Kidney Diseases Application
Application Receipt Dates(s): November 22, 2016
Website: http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-16-023.html
NIH Director's New Innovator Award Program (DP2) (RFA-RM-16-004)
Description: The NIH Director’s New Innovator (DP2) Award initiative supports a small number of early stage investigators of exceptional creativity who propose bold and highly innovative new research approaches that have the potential to produce a major impact on broad, important problems in biomedical and behavioral research. The New Innovator Award initiative complements ongoing efforts by NIH and its Institutes and Centers to fund early stage investigators through R01 grants, which continue to be the major sources of NIH support for early stage investigators. The NIH Director’s New Innovator Award initiative is a component of the High Risk - High Reward Research Program of the NIH Common Fund.
Sponsor(s): NIH Roadmap Initiatives, The Common Fund/Office of Strategic Coordination
Application Receipt Dates(s): September 09, 2016
Website: http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-16-004.html
NIH Director’s Pioneer Award Program (DP1) (RFA-RM-16-005)
Description: The NIH Director’s Pioneer Award initiative complements NIH's traditional, investigator-initiated grant programs by supporting individual scientists of exceptional creativity who propose pioneering and possibly transforming approaches to addressing major biomedical or behavioral challenges that have the potential to produce an unusually high impact on enhancing health, lengthening life, and reducing illness and disability. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigator’s research program or elsewhere.
Sponsor(s): NIH Roadmap Initiatives
Application Receipt Dates(s): September 02, 2016
Website: http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-16-005.html
NIH Director's Transformative Research Awards (R01) (RFA-RM-16-007)
Description: The NIH Director's Transformative Research Awards complement NIH’s traditional, investigator-initiated grant programs by supporting individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. Little or no preliminary data are expected. Projects must clearly demonstrate the potential to produce a major impact in a broad area of biomedical or behavioral research.
Sponsor(s): NIH Roadmap Initiatives, The Common Fund/Office of Strategic Coordination
Application Receipt Dates(s): October 07, 2016
Website: http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-16-007.html
NIDDK Program Projects (P01) (PAR-16-127)
Description: This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated program project applications. The proposed programs should address scientific areas relevant to the NIDDK mission including diabetes, selected endocrine and metabolic diseases, obesity, digestive diseases and nutrition, and kidney, urologic and hematologic diseases, as well as new approaches to prevent, treat and cure these diseases, including clinical research.
Sponsor(s): National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Dates(s): Multiple dates, see announcement.
Website: https://grants.nih.gov/grants/guide/pa-files/PAR-16-127.html
High Impact, Interdisciplinary Science in NIDDK Research Areas (RC2) (PAR-16-126)
Description: The purpose of the High Impact, Interdisciplinary Science grants program is to support high impact ideas that may lay the foundation for new fields of investigation within the mission of NIDDK. The interdisciplinary approach encouraged by this FOA is envisioned to generate a community research resource for the broader community, which may include discovery-based or hypothesis-generating science. The interdisciplinary research team should be able to provide an integrative plan of working together to effectively address the complex challenge at hand. This program will support research projects that accelerate critical breakthroughs, early and applied research on cutting-edge technologies, and new approaches to improve the synergy and interactions among multi- and interdisciplinary research teams, including sharing of data and other resources to further advance research in this area. This FOA seeks novel approaches in areas that address specific knowledge gaps, scientific opportunities, new technologies, data generation, or research methods that will advance the area in significant ways designed to accelerate scientific progress in the understanding, treatment and prevention of diseases within the mission of NIDDK.
Sponsor(s): National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Dates(s): June 1, 2016; November 1, 2016; June 1, 2017; November 1, 2017; June 1, 2018; November 1, 2018, by 5:00 PM local time of applicant organization.
Website: https://grants.nih.gov/grants/guide/pa-files/PAR-16-126.html
JDRF – Generating Improved Beta/Islet Cell Sources Through Genetic Modifications ($1,050,000 award)
Description: The objective of this RFA is to support applications to use state-of-the-art gene modification techniques to develop and test improved beta/islet cell preparations, with a pathway toward therapeutic use in beta cell replacement for T1D patients. Applications selected for funding will foster multidisciplinary collaborations that are required for translational research to develop a safe and effective cell based therapy for beta cell replacement for treating T1D. A successful team will ideally draw upon expertise from investigators established in stem cell biology, beta cell biology, immunology, transplantation, and/or diabetology. To achieve this, JDRF is soliciting proposals addressing aspects of the following (not intended to be exclusive or all-encompassing): Gene modifications to enhance beta/islet cell preparations; Imparting protection from allo- or xeno-geneic rejection or autoimmune destruction; Increasing the cell’s resistance to stress; Enhancing cell preparation’s safety profile with suicide switches; Development of in vitro tools and in vivo models that can have predictive values on whether the modified cells can withstand human immune responses in the clinical setting; Demonstration of the intended effects by the modifications in vitro and in vivo while balancing minimal number of modifications with efficacy and minimizing off-target mutations. NOTE: there will be a Q&A Teleconference at 11:00 AM on March 9th (please see grants report summary for full details).
Sponsor(s): JDRF
Application Receipt Dates(s): April 28, 2016
Website: http://grantcenter.jdrf.org/wp-content/uploads/2012/12/Generating-Improved-Beta-Islet-Cell-Sources-Through-Genetic-Modifications-RFA.pdf
Improving Diabetes Management in Pre-teens, Adolescents and/or Young Adults with Type 1 Diabetes (DP3) (RFA-DK-16-001)
Description: The goal of this FOA is to encourage applications from institutions/organizations proposing to develop, refine, and pilot test innovative strategies to improve diabetes management in pre-teens (ages 10-12), adolescents (ages 13-18) and/or young adults (ages 19-30) with type 1 diabetes. At the end of the funding period, there should be a well-developed and well-characterized intervention that has been demonstrated to be safe, feasible to implement, acceptable in the target population, and, if promising, ready to be tested in a larger efficacy trial.
Sponsor(s): National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Dates(s): June 22, 2016
Website: http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-16-001.html
Understanding Barriers and Facilitators to Type 1 Diabetes Management in Adults (DP3) (RFA-DK-16-002)
Description: The goal of this Funding Opportunity Announcement (FOA) is to support research that will identify barriers and facilitators to good diabetes self-management in adults with type 1 diabetes. The results from this research should inform future intervention research in adults with type 1 diabetes.
Sponsor(s): National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Dates(s): June 22, 2016
Website: http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-16-002.html
Improving Diabetes Management in Children with Type 1 Diabetes (DP3) (RFA-DK-16-003)
Description: The goal of this Funding Opportunity Announcement (FOA) is to support research to develop, refine, and pilot test innovative strategies to improve management of type 1 diabetes in young children (under 5 years old) and/or school-aged children (ages 5-9 years old). At the end of the funding period, there should be a well-developed and well-characterized intervention that has been demonstrated to be safe, feasible to implement, acceptable in the target population, and, if promising, ready to be tested in a larger efficacy trial.
Sponsor(s): National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Dates(s): June 22, 2016
Website: http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-16-003.html
Diabetic Complications Consortium (DiaComp) Pilot and Feasibility Program
Description: This program solicits and funds small Pilot and Feasibility (P&F) projects in high impact areas of complications research. Specifically, this program aims to support discovery (hypothesis generating) and innovative (high risk/ high reward) research that is increasingly difficult to support through standard NIH mechanisms. Basic, translational and clinical research proposals are encouraged.
Sponsor(s): NIDDK
Application Receipt Dates(s): Friday, May 13, 2016.
Website: http://www.diacomp.org/shared/pilotFeasibility.aspx
Metabolomics Data Analysis (R03) (RFA-RM-15-021)
Description: In a continuing effort to improve the use of metabolomics in biomedical research, the NIH Common Fund Metabolomics Program has released a Metabolomics Data Analysis Funding Opportunity Announcement (FOA). This FOA is intended to support secondary analysis of existing metabolomics datasets and/or promote the development of new or improved approaches to metabolomics data analysis through collaborations between bioinformaticians, biostatisticians, metabolomics experts, and/or biomedical researchers. These one-year, $100K, grants are also intended to complement the current efforts of the Common Fund Metabolomics Program and maximize the value of existing metabolomics databases and resources.
Sponsor(s): National Institutes of Health (NIH)
Application Receipt Dates(s): February 11, 2016
Website: http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-15-021.html
TACT2: Trial to Assess Chelation Therapy
Description: TACT2 follows up the positive results of TACT, an NIH-sponsored multicenter, double-blind efficacy trial; TACT2 is currently in a planning year funded by NCCIH; We are looking for trial sites to enroll, infuse and follow patients
Contact: For more information, contact the Study Chairman, Dr. Gervasio Lamas, at gervasiolamas@gmail.com, @GLamasMD on Twitter, or (305) 674-2260.
PDF: TACT2 Trial Site Information.pdf
Elucidating HIV and HIV-treatment Associated Metabolic/Endocrine Dysfunction (R01) (RFA-DK-16-014)
Sponsor(s): National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Dates(s): March 9, 2016
Website: http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-16-014.html
Human Pancreas Procurement and Analysis Program (HPPAP) (UC4) (RFA-DK-15-027)
Sponsor(s): National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Dates(s): March 3, 2016
Website: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-15-027.html
Biomarkers for Diabetes, Digestive, Kidney and Urologic Diseases Using Biosamples from the NIDDK Repository (R01) (PAR-13-228)
Sponsor(s): National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Dates(s): Standard - June 5, 2015; October 5, 2015; February 5, 2016; June 5, 2016; and October 5, 2016
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-13-228.html
Translational Research to Improve Diabetes and Obesity Outcomes (R01) (PA-13-352)
Sponsor(s): National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Dates(s): Standard - June 5, 2015; October 5, 2015; February 5, 2016; June 5, 2016; and October 5, 2016
Website: http://grants.nih.gov/grants/guide/pa-files/PA-13-352.html
Evaluating Natural Experiments in Healthcare to Improve Diabetes Prevention and Treatment (R18) (PAR-13-365)
Sponsor(s): National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Dates(s): July 1, 2015; November 2, 2015; March 1, 2016; July 1, 2016; and November 1, 2016
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-13-365.html
Pragmatic Research in Healthcare Settings to Improve Diabetes Prevention and Care (R18)(PAR-13-366)
Sponsor(s): National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Dates(s): July 1, 2015; November 2, 2015; March 1, 2016; July 1, 2016; and November 1, 2016
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-13-366.html
Planning Grants for Pragmatic Research in Healthcare Settings to Improve Diabetes Prevention and Care (R34) (PAR-13-367)
Sponsor(s): National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Dates(s): July 1, 2015; November 2, 2015; March 1, 2016; July 1, 2016; and November 1, 2016
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-13-367.html

Please visit http://www2.niddk.nih.gov/Funding/ for a complete list of NIDDK funding opportunities.

Please visit http://grants.nih.gov for a complete list of active diabetes-related grants and funding from NIH.